Coagulation in Hematological Malignancies

REFERENCES

• Falanga A., Rickles F. R. Management of thrombohemorrhagic syndromes (THS) in hematologic malignancies. Hematology Am Soc Hematol Educ Program 2007; 165–71
   PubMedGoogle Scholar
• Falanga A., Marchetti M. Thromboembolism in hematologic malignancies. Cancer-Associated Thrombosis, A. A. Khorana, C. W. Francis. Informa Healthcare, New York, NY 2008; 131–149
   Google Scholar
• White R. H., Chew H. K., Zhou H., Parikh-Patel A., Harris D., Harvey D., Wun T. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528693 adults. Arch Intern Med 2005; 165: 1782–1787
   PubMed Web of Science ®Google Scholar
• Khorana A. A., Francis C. W., Culakova E., Lyman G. H. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005; 104: 2822–2829
   PubMed Web of Science ®Google Scholar
• Khorana A. A., Francis C. W., Culakova E., Fisher R. I., Kuderer N. M., Lyman G. H. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Onc 2006; 24: 484–490
   PubMed Web of Science ®Google Scholar
• Falanga A., Marchetti M. Oncology. Practical Hemostasis and Thrombosis, M. O'Shaughnessy, D. Makris Lillicrap. Blackwell Publishing. 2005; 190–200, Chapter 20
   Google Scholar
• Palumbo A., Rajkumar S. V., Dimopoulos M. A., Richardson P. G., San Miguel J., Barlogie B., Harousseau J., Zonder J. A., Cavo M., Zangari M., Attal M., Belch A., Knop S., Joshua D., Sezer O., Ludwig H., Vesole D., Bladé J., Kyle R., Westin J., Weber D., Bringhen S., Niesvizky R., Waage A., von Lilienfeld-Toal M., Lonial S., Morgan G. J., Orlowski R. Z., Shimizu K., Anderson K. C., Boccadoro M., Durie B. G., Sonneveld P., Hussein M. A. International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414–423
   PubMed Web of Science ®Google Scholar
• Cortelezzi A., Moia M., Falanga A., Pogliani E. M., Agnelli G., Bonizzoni E., Gussoni G., Barbui T., Mannucci P. M., CATHEM Study Group. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Brit J Hematol 2005; 129: 811–817
   PubMed Web of Science ®Google Scholar
• Couban S., Goodyear M., Burnell M., Dolan S., Wasi P., Barnes D., Macleod D., Burton E., Andreou P., Anderson D. R. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter–associated thrombosis in patients with cancer. J Clin Oncol 2005; 23: 4063–4069
   PubMed Web of Science ®Google Scholar
• Falanga A., Barbui T., Rickles F. R. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. Semin Thromb Hemost 2008; 34: 204–210
   PubMed Web of Science ®Google Scholar
• Clarke C. S., Otridge B. W., Carney D. N. Thromboembolism. A complication of weekly chemotherapy in the treatment of non-Hodgkin's lymphoma. Cancer 1990; 66: 2027–2030
   PubMed Web of Science ®Google Scholar
• Ottinger H., Belka C., Kozole G., Engelhard M., Meusers P., Paar D., Metz K. A., Leder L. D., Cyrus C., Gnoth S., et al. Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin's lymphoma: incidence, causes and prognostic relevance. Eur J Haematol 1995; 54: 186–194
   PubMed Web of Science ®Google Scholar
• Mohren M., Markmann I., Jentsch-Ullrich K., Koenigsmann M., Lutze G., Franke A. Increased risk of thromboembolism in patients with malignant lymphoma: a single-centre analysis. Br J Cancer 2005; 92: 1349–1351
   PubMed Web of Science ®Google Scholar
• Komrokji R. S., Uppal N. P., Khorana A. A., Lyman G. H., Kaplan K. L., Fisher R. I., Francis C. W. Venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2006; 47: 1029–1033
   PubMed Web of Science ®Google Scholar
• Goldschmidt N., Linetsky E., Shalom E., Varon D., Siegal T. High incidence of thromboembolism in patients with central nervous system lymphoma. Cancer 2003; 98: 1239–1242
   PubMed Web of Science ®Google Scholar
• Athale U. H., Nagel K., Khan A. A., Chan A. K. Thromboembolism in children with lymphoma. Thromb Res 2008; 122: 459–465
   PubMed Web of Science ®Google Scholar
• Ziegler S., Sperr W. R., Knöbl P., Lehr S., Weltermann A., Jäger U., Valent P., Lechner K. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis. Thromb Res 2005; 115: 59–64
   Google Scholar
• De Stefano V., Sorà F., Rossi E., Chiusolo P., Laurenti L., Fianchi L., Zini G., Pagano L., Sica S., Leone G. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 2005; 3: 1985–1992
   PubMed Web of Science ®Google Scholar
• Melillo L., Grandone E., Colaizzo D., Cappucci F., Valvano M. R., Cascavilla N. Symptomatic venous thromboembolism and thrombophilic status in adult acute leukemia: a single-center experience of 114 patients at diagnosis. Acta Haematol 2007; 117: 215–220
   PubMed Web of Science ®Google Scholar
• Mohren M., Markmann I., Jentsch-Ullrich K., Koenigsmann M., Lutze G., Franke A. Increased risk of venous thromboembolism in patients with acute leukemia. Br J Cancer 2006; 94: 200–202
   PubMed Web of Science ®Google Scholar
• Caruso V., Iacoviello L., Di Castelnuovo A., Storti S., Donati M. B. Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis. J Thromb Haemost 2007; 5: 621–623
   PubMed Web of Science ®Google Scholar
• Rodeghiero F., Avvisati G., Castaman G., Barbui T., Mandelli M. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 1990; 75: 2112–2117
   PubMed Web of Science ®Google Scholar
• Falanga A., Rickles F. R. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003; 16: 463–482
   PubMed Web of Science ®Google Scholar
• de la Serna J., Montesinos P., Vellenga E., Rayón C., Parody R., León A., Esteve J., Bergua J. M., Milone G., Debén G., Rivas C., González M., Tormo M., Díaz-Mediavilla J., González J. D., Negri S., Amutio E., Brunet S., Lowenberg B., Sanz M. A. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008; 111: 3395–3402
   PubMed Web of Science ®Google Scholar
• Rickles F. R., Falanga A., Montesinos P., Sanz M. A., Brenner B., Barbui T. Bleeding and thrombosis in acute leukemia: What does the future of therapy look like?. Thromb Res 2007; 120(Suppl. 2)S99–S106
   PubMedGoogle Scholar
• Priest J. R., Ramsay N. K., Steinherz P. G., Tubergen D. G., Cairo M. S., Sitarz A. L., Bishop A. J., White L., Trigg M. E., Levitt C. J., Cich J. A., Coccia P. F. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr 1982; 100: 984–989
   PubMed Web of Science ®Google Scholar
• Pui C. H., Jackson C. W., Chesney C., Lyles S. A., Bowman W. P., Abromowitch M., Simone J. V. Sequential changes in platelet function and coagulation in leukemic children treated with L-asparaginase, prednisone and vincristine. J Clin Oncol 1983; 1: 380–385
   PubMed Web of Science ®Google Scholar
• Nowak-Göttl U., Wermes C., Junker R., Koch H. G., Schobess R., Fleischhack G., Schwabe D., Ehrenforth S. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further thrombotic risk factors. Blood 1999; 93: 1595–1599
   PubMed Web of Science ®Google Scholar
• Caruso V., Iacoviello L., Di Castelnuovo A., Storti S., Mariani G., de Gaetan G., Donati M. B. Thrombotic complications in childhood acute lymphoblastic leukcemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006; 108: 2216–2222
   PubMed Web of Science ®Google Scholar
• Annino L., Vegna M. L., Camera A., Specchia G., Visani G., Fioritoni G., Ferrara F., Peta A., Ciolli S., Deplano W., Fabbiano F., Sica S., Di Raimondo F., Cascavilla N., Tabilio A., Leoni P., Invernizzi R., Baccarani M., Rotoli B., Amadori S., Mandelli F., GIMEMA Group. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002; 99: 863–871
   PubMed Web of Science ®Google Scholar
• Sarris A. H., Kempin S., Berman E., Michaeli J., Little C., Andreeff M., Gee T., Straus D., Gansbacher B., Filippa D., Glaser B., Clarkson B. High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood 1992; 79: 1305–1310
   PubMed Web of Science ®Google Scholar
• Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., Munshi N., Anaissie E., Wilson C., Dhodapkar M., Zeddis J., Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571
   PubMed Web of Science ®Google Scholar
• Barlogie B., Tricot G., Anaissie E., Shaughnessy J., Rasmussen E., van Rhee F., Fassas A., Zangari M., Hollmig K., Pineda-Roman M., Lee C., Talamo G., Thertulien R., Kiwan E., Krishna S., Fox M., Crowley J. Thalidomide and hematopoietic-celltranplantation for multiple myeloma. N Engl J Med 2006; 354: 1021–1030
   PubMed Web of Science ®Google Scholar
• Weber D., Rankin K., Gavino M., Delasalle K., Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16–19
   PubMed Web of Science ®Google Scholar
• Rajkumar S. V., Gertz M. A., Lacy M. Q., Dispenzieri A., Fonseca R., Geyer S. M., Iturria N., Kumar S., Lust J. A., Kyle R. A., Greipp P. R., Witzig T. E. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775–779
   PubMed Web of Science ®Google Scholar
• Barlogie B., Desikan R., Eddlemon P., Spencer T., Zeldis J., Munshi N., Badros A., Zangari M., Anaissie E., Epstein J., Shaughnessy J., Ayers D., Spoon D., Tricot G. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492–494
   PubMed Web of Science ®Google Scholar
• Neben K., Moehler T., Benner A., Kraemer A., Egerer G., Ho A. D., Goldschmidt H. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002; 8: 3377–3382
   PubMed Web of Science ®Google Scholar
• Schey S. A., Cavenagh J., Johnson R., Child J. A., Oakervee H., Jones R. W. An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leuk Res 2003; 27: 909–914
   PubMed Web of Science ®Google Scholar
• Osman K., Comenzo R., Rajkumar S. V. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 2001; 344: 1951–1952
   PubMed Web of Science ®Google Scholar
• Rajkumar S. V., Blood E., Vesole D., Fonseca R., Greipp P. R., Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431–436
   PubMed Web of Science ®Google Scholar
• Cavo M., Zamagni E., Tosi P., Cellini C., Cangini D., Tacchetti P., Testoni N., Tonelli M., de Vivo A., Palareti G., Tura S., Baccarani M. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89: 826–831
   PubMed Web of Science ®Google Scholar
• Palumbo A., Bertola A., Falco P., Rosato R., Cavallo F., Giaccone L., Bringhen S., Musto P., Pregno P., Caravita T., Ciccone G., Boccadoro M. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 2004; 5: 318–324
   PubMedGoogle Scholar
• Anagnostopoulos A., Weber D., Rankin K., Delasalle K., Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003; 121: 768–771
   PubMed Web of Science ®Google Scholar
• Rus C., Bazzan M., Palumbo A., Bringhen S., Boccadoro M. Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis. J Thromb Haemost 2004; 2: 2063–2065
   PubMed Web of Science ®Google Scholar
• Zangari M., Anaissie E., Barlogie B. Increased risk of deep vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614–1615
   PubMed Web of Science ®Google Scholar
• Zangari M., Saghafifar F., Anaissie E., Badros A., Desikan R., Fassas A., Mehta P., Morris C., Toor A., Whitfield D., Siegel E., Barlogie B., Fink L., Tricot G. Activated protein C in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 2002; 13: 187–192
   PubMed Web of Science ®Google Scholar
• Dimopoulos M. A., Anagnostopoulos A., Terpos E., Repoussis P., Zomas A., Katodritou E., Kyrtsonis M. C., Delibasi S., Vassou A., Pouli A., Zervas K., Anagnostopoulos N., Maniatis A., Greek Myeloma Study Group. Primary treatmente with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica 2006; 91: 252–254
   PubMed Web of Science ®Google Scholar
• Zervas K., Dimopoulos M. A., Hatzicharissi E., Anagnostopoulos A., Papaioannou M., Mitsouli Ch., Panagiotidis P., Korantzis J., Tzilianos M., Maniatis A., Greek Myeloma Study Group. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexhamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol 2004; 15: 134–138
   PubMed Web of Science ®Google Scholar
• Sidra G., Williams C. D., Russell N. H., Zaman S., Myers B., Byrne J. L. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica 2006; 91: 862–863
   PubMed Web of Science ®Google Scholar
• Baz R., Li L., Kottke-Marchant K., Srkalovic G., McGowan B., Yiannaki E., Kara M. A., Faiman B., Jawde R. A., Andresen S., Zeldis J., Hussein M. A. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005; 80: 1568–1574
   PubMed Web of Science ®Google Scholar
• Offidani M., Corvatta L., Marconi M., Olivieri A., Catarini M., Mele A., Brunori M., Candela M., Malerba L., Capelli D., Montanari M., Leoni P. Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. Hematol J 2004; 5: 312–317
   PubMedGoogle Scholar
• Dimopoulos M. A., Hamilos G., Zomas A., Gika D., Efstathiou E., Grigoraki V., Poziopoulos C., Xilouri I., Zorzou M. P., Anagnostopoulos N., Anagnostopoulos A. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for prviously treated patients with multiple myeloma. Hematol J 2004; 5: 112–117
   PubMedGoogle Scholar
• García-Sanz R., González-Porras J. R., Hernández J. M., Polo-Zarzuela M., Sureda A., Barrenetxea C., Palomera L., López R., Grande-García C., Alegre A., Vargas-Pabón M., Gutiérrez O. N., Rodríguez J. A., San Miguel J F. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004; 18: 856–863
   PubMed Web of Science ®Google Scholar
• Kropff M. H., Lang N., Bisping G., Dominé N., Innig G., Hentrich M., Mitterer M., Südhoff T., Fenk R., Straka C., Heinecke A., Koch O. M., Ostermann H., Berdel W. E., Kienast J. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 2003; 122: 607–616
   PubMed Web of Science ®Google Scholar
• Suvannasankha A., Fausel C., Juliar B. E., Yiannoutsos C. T., Fisher W. B., Ansari R. H., Wood L. L., Smith G. G., Cripe L. D., Abonour R. Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: a Hoosier oncology group trial, HEM01-21. Oncologist 2007; 12: 99–106
   PubMed Web of Science ®Google Scholar
• Zangari M., Barlogie B., Thertulien R., Jacobson J., Eddleman P., Fink L., Fassas A., Van Rhee F., Talamo G., Lee C. K., Tricot G. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma 2003; 4: 32–35
   PubMedGoogle Scholar
• Urbauer E., Kaufmann H., Nosslinger T., Nösslinger T., Raderer M., Drach J. Thromboembolic events during treatment with thalidomide. Blood 2002; 99: 4247–4248
   PubMed Web of Science ®Google Scholar
• Richardson P. G., Blood E., Mitsiades C. S., Jagannath S., Zeldenrust S. R., Alsina M., Schlossman R. L., Rajkumar S. V., Desikan K. R., Hideshima T., Munshi N. C., Kelly-Colson K., Doss D., McKenney M. L., Gorelik S., Warren D., Freeman A., Rich R., Wu A., Olesnyckyj M., Wride K., Dalton W. S., Zeldis J., Knight R., Weller E., Anderson K. C. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458–3464
   PubMed Web of Science ®Google Scholar
• Zonder J. A., Durie B. G. M., McCoy J., Crowley J., Hussein M. A. High incidence of thrombotic events observed in patients receiving lenalidomide (L) + dexamethasone (D) (LD) as first-line therapy for multiple myeloma (MM) without aspirin (ASA) prophylaxis. ASH annual meeting. Blood 2005; 106: 3455
   Google Scholar
• Menon S. P., Rajkumar S. V., Lacy M., Falco P., Palumbo A. Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer 2008; 112: 1522–1528
   PubMed Web of Science ®Google Scholar
• Rajkumar S. V., Jacobus S., Callander N., Fonseca R., Vesole D., Williams M., Abonour R., Siegel S., Greipp P. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. J Clin Oncol 2007; 25(18 Suppl.), LBA8025
   Google Scholar
• Dimopoulos M., Spencer A., Attal M., Prince H. M., Harousseau J. L., Dmoszynska A., San Miguel J., Hellmann A., Facon T., Foà R., Corso A., Masliak Z., Olesnyckyj M., Yu Z., Patin J., Zeldis J. B., Knight R. D., Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123–2132
   PubMed Web of Science ®Google Scholar
• Weber D. M., Chen C., Niesvizky R., Wang M., Belch A., Stadtmauer E. A., Siegel D., Borrello I., Rajkumar S. V., Chanan-Khan A. A., Lonial S., Yu Z., Patin J., Olesnyckyj M., Zeldis J. B., Knight R. D., Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133–2142
   PubMed Web of Science ®Google Scholar
• Falanga A., Ofosu F. A., Delaini F., Oldani E., Dewar L., Lui L., Barbui T. The hypercoagulable state in cancer: evidence for impaired thrombin inhibition. Blood Coag & Fibr 1994; 5: S19–S23
   PubMed Web of Science ®Google Scholar
• Falanga A., Marchetti M., Vignoli A., Balducci D. Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. Clin Adv Hematol Oncol 2003; 1: 673–678
   PubMedGoogle Scholar
• De Lucia D., De Francesco F., Marotta R., Maisto G., Meo D., Sessa M., Misso M., Galante M., Russo T., Pignalosa O., Napolitano M., Papa M. L., Niglio A., Di Micco P. Phenotypic APC resistance as a marker of hypercoagulability in primitive cerebral lymphoma. Exp Oncol 2005; 27: 159–161
   PubMed Web of Science ®Google Scholar
• Sase T., Wada H., Yamaguchi M., Ogawa S., Kamikura Y., Nishikawa M., Kaneko T., Abe Y., Nishioka J., Nobori T., Shiku H. Haemostatic abnormalities and thrombotic disorders in malignant lymphoma. Thromb Haemost 2005; 93: 153–159
   PubMed Web of Science ®Google Scholar
• Minnema M. C., Fijnheer R., De Groot P. G., Lokhorst H. M. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003; 1: 445–449
   PubMed Web of Science ®Google Scholar
• Hugo J. Z., Jeanet D. M. Acquired activated protein C resistance and thrombosis in multiple myeloma patients. Thromb J 2006; 21: 4–11
   Google Scholar
• Elice F., Fink L., Tricot G., Barlogie B., Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006; 134: 399–405
   PubMed Web of Science ®Google Scholar
• van Marion A. M., Auwerda J. J., Minnema M. C., van Oosterom R., Adelmeijer J., de Groot P. G., Leebeek F. W., Sonneveld P., Lokhorst H. M., Lisman T. Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thromb Haemost 2005; 94: 1341–1343
   PubMed Web of Science ®Google Scholar
• Leone G., Gugliotta L., Mazzucconi M. G., De Stefano V., Belmonte M. M., Dragoni F., Specchia G., Centra A., Gamba G., Camera A., et al. Evidence of a hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E. coli L-Asparaginase: a GIMEMA study. Thromb Haemost 1993; 69: 12–15
   PubMed Web of Science ®Google Scholar
• Warrell R. P., de The H., Wang Z. Y., Degos L. Acute promyelocytic leukemia. N Engl J Med 1993; 329: 177–189
   PubMed Web of Science ®Google Scholar
• Castaigne S., Chomienne C., Daniel M. T., Ballerini P., Berger R., Fenaux P., Degos L. All-trans retinoic acid as a differentation therapy for acute promyelocytic leukemia. Blood 1990; 76: 1704–1709
   PubMed Web of Science ®Google Scholar
• Falanga A., Iacoviello L., Evangelista V., Belotti D., Consonni R., D'Orazio A., Robba L., Donati M. B., Barbui T. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocitic leukemia given all-trans-retinoic acid. Blood 1995; 86: 1072–1084
   PubMed Web of Science ®Google Scholar
• Tallman M. S., Lefèbvre P., Baine R. M., Shoji M., Cohen I., Green D., Kwaan H. C., Paietta E., Rickles F. R. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocitic leukemia. J Thromb Haemost 2004; 2: 1341–1350
   PubMed Web of Science ®Google Scholar
• Dombret H., Scrobohaci M. L., Daniel M. T., Micléa J. M., Castaigne S., Chomienne C., Fenaux P., Degos L. In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy. Leukemia 1995; 9: 19–24
   PubMed Web of Science ®Google Scholar
• Lee A. Y., Levine M. N. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999; 25: 137–145
   PubMed Web of Science ®Google Scholar
• Zangari M., Saghafifar F., Mehta P., Barlogie B., Fink L., Tricot G. The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost 2003; 29: 275–282
   PubMed Web of Science ®Google Scholar
• Wang M., Weber D. M., Delasalle K., Alexanian R. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol 2005; 79: 194–197
   PubMed Web of Science ®Google Scholar
• Palumbo A., Bringhen S., Caravita T., Merla E., Capparella V., Callea V., Cangialosi C., Grasso M., Rossini F., Galli M., Catalano L., Zamagni E., Petrucci M. T., De Stefano V., Ceccarelli M., Ambrosini M. T., Avonto I., Falco P., Ciccone G., Liberati A. M., Musto P., Boccadoro M., Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825–831
   PubMed Web of Science ®Google Scholar
• Minnema M. C., Breitkreutz I., Auwerda J. J., van der Holt B., Cremer F. W., van Marion A. M., Westveer P. H., Sonneveld P., Goldschmidt H., Lokhorst H. M. Prevention of venous thromboembolism with low molecular-weight hepatin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004; 18: 2044–2046
   PubMed Web of Science ®Google Scholar
• Offidani M., Corvatta L., Piersantelli M. N., Visani G., Alesiani F., Brunori M., Galieni P., Catarini M., Burattini M., Centurioni R., Ferranti M., Rupoli S., Scortechini A. R., Giuliodori L., Candela M., Capelli D., Montanari M., Olivieri A., Poloni A., Polloni C., Marconi M., Leoni P. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 2006; 108: 2159–2164
   PubMed Web of Science ®Google Scholar
• Zangari M., Barlogie B., Anaissie E., Saghafifar F., Eddlemon P., Jacobson J., Lee C. K., Thertulien R., Talamo G., Thomas T., Van Rhee F., Fassas A., Fink L., Tricot G. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004; 126: 715–721
   PubMed Web of Science ®Google Scholar
• Lyman G. H., Khorana A. A., Falanga A., Clarke-Pearson D., Flowers C., Jahanzeb M., Kakkar A., Kuderer N. M., Levine M. N., Liebman H., Mendelson D., Raskob G., Somerfield M. R., Thodiyil P., Trent D., Francis C. W., American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490–5505
   PubMed Web of Science ®Google Scholar
• Lee A. Y. Y., Levine M. N., Baker R. I., Bowden C., Kakkar A. K., Prins M., Rickles F. R., Julian J. A., Haley S., Kovacs M. J., Gent M. Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146–153
   PubMed Web of Science ®Google Scholar